Skip to main content
SpringerLink
Log in

Treatment Modalities for Cutaneous and Visceral Leishmaniasis

  • Chapter
  • First Online:
Pathogenesis of Leishmaniasis

  • 801 Accesses

Abstract

The annual incidence of cutaneous and visceral leishmaniasis is at least two million people, with 350 million people in 98 countries at risk for acquiring infection. These are diseases mostly of the impoverished and are considered in the top five of neglected infectious diseases worldwide, making prevention, diagnosis, and treatment difficult. Therapy of leishmaniasis ranges from local treatment of cutaneous lesions to systemic, often toxic, therapy for disseminated cutaneous, mucocutaneous, and deadly visceral disease. This chapter discusses the current treatment regimens commonly used for various forms of leishmaniasis with attention to some promising newer experimental approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346:891–895

    Article  CAS  PubMed  Google Scholar 

  • Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A et al (2007) Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157:1032–1036

    Article  CAS  PubMed  Google Scholar 

  • Arana BA, Mendoza CE, Rizzo NR, Kroeger A (2001) Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65:466–470

    CAS  PubMed  Google Scholar 

  • Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E et al (2001) Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 33:1847–1851

    Article  CAS  PubMed  Google Scholar 

  • Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A et al (2007) Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44:1549–1554

    Article  CAS  PubMed  Google Scholar 

  • Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A (2003) The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 97:493–498

    Article  CAS  PubMed  Google Scholar 

  • Asilian A, Sadeghinia A, Faghihi G, Momeni A (2004) Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 43:281–283

    Article  CAS  PubMed  Google Scholar 

  • Badaro R, Lobo I, Nakatani M, Muinos A, Netto EM, Coler RN et al (2001) Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 5:223–232

    CAS  PubMed  Google Scholar 

  • Badaro R, Lobo I, Munos A, Netto EM, Modabber F, Campos-Neto A et al (2006) Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 194:1151–1159

    Article  CAS  PubMed  Google Scholar 

  • Baiocco P, Colotti G, Franceschini S, Ilari A (2009) Molecular basis of antimony treatment in leishmaniasis. J Med Chem 52:2603–2612

    Article  CAS  PubMed  Google Scholar 

  • Barratt G, Legrand P (2005) Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr Opin Infect Dis 18:527–530

    Article  CAS  PubMed  Google Scholar 

  • Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J et al (2013) Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368:524–532

    Article  CAS  PubMed  Google Scholar 

  • Bringaud F, Riviere L, Coustou V (2006) Energy metabolism of trypanosomatids: adaptation to available carbon sources. Mol Biochem Parasitol 149:1–9

    Article  CAS  PubMed  Google Scholar 

  • Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC et al (2013) Long-term efficacy of a single-dose Radio Frequency Heat therapy versus intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol 168(5):1114–1119

    Article  CAS  PubMed  Google Scholar 

  • Calvopina M, Armijos RX, Hashiguchi Y (2004) Epidemiology of leishmaniasis in Ecuador: current status of knowledge—a review. Mem Inst Oswaldo Cruz 99:663–672

    Article  PubMed  Google Scholar 

  • Center for Disease Control (1992) Viscerotropic leishmaniasis in persons returning from Operation Desert Storm—1990–1991. MMWR Morb Mortal Wkly Rep 41:131–134

    Google Scholar 

  • Chang KP, Dwyer DM (1976) Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science 193:678–680

    Article  CAS  PubMed  Google Scholar 

  • Chang KP, Reed SG, McGwire BS, Soong L (2003) Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85:375–390

    Article  PubMed  Google Scholar 

  • Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M et al (2003) Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–99. Trans R Soc Trop Med Hyg 97:469–472

    Article  CAS  PubMed  Google Scholar 

  • Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, Mazzedo MI et al (2004) Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz 99:57–62

    Article  PubMed  Google Scholar 

  • Cunningham ML, Beverley SM (2001) Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy. Mol Biochem Parasitol 113:199–213

    Article  CAS  PubMed  Google Scholar 

  • Das BB, Sengupta T, Ganguly A, Majumder HK (2006) Topoisomerases of kinetoplastid parasites: why so fascinating? Mol Microbiol 62:917–927

    Article  CAS  PubMed  Google Scholar 

  • David CV, Craft N (2009) Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther 22:491–502

    Article  PubMed  Google Scholar 

  • de Oliveira CI, Brodskyn CI (2012) The immunobiology of Leishmania braziliensis infection. Front Immunol 3:145

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Esfandiarpour I, Dabiri SH (2007) Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol 46:848–852

    Article  PubMed  Google Scholar 

  • Expert Committee, Control of the leishmaniases. WHO Technical Report Series 949. World Health Organization, Geneva, Switzerland, 2010, pp 1–186

    Google Scholar 

  • Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985) Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227:1485–1487

    Article  CAS  PubMed  Google Scholar 

  • Fidalgo LM, Gille L (2011) Mitochondria and trypanosomatids: targets and drugs. Pharm Res 28:2758–2770

    Article  CAS  PubMed  Google Scholar 

  • Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A et al (2006) Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 142:1575–1579

    CAS  PubMed  Google Scholar 

  • Garcia Bustos MF, Barrio AB, Parodi Ramoneda CM, Ramos F, Mora MC, Convit J et al (2011) Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report. Invest Clin 52:365–375

    PubMed  Google Scholar 

  • Gonzalez U, Pinart M, Reveiz L, Alvar J (2008) Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (4):CD005067

    Google Scholar 

  • Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA (2009) Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev:CD004834

    Google Scholar 

  • Goto H, Lauletta Lindoso JA (2012) Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 26:293–307

    Article  PubMed  Google Scholar 

  • Hartley MA, Kohl K, Ronet C, Fasel N (2013) The therapeutic potential of immune cross-talk in leishmaniasis. Clin Microbiol Infect 19:119–130

    Article  CAS  PubMed  Google Scholar 

  • Hellier I, Dereure O, Tournillac I, Pratlong F, Guillot B, Dedet JP et al (2000) Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 200:120–123

    Article  CAS  PubMed  Google Scholar 

  • Hervas JA, Martin-Santiago A, Hervas D, Rojo E, Mena A, Rocamora V et al (2012) Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Pediatr Infect Dis J 31:97–100

    Article  PubMed  Google Scholar 

  • Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C et al (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795–1800

    Article  CAS  PubMed  Google Scholar 

  • Krauth-Siegel RL, Inhoff O (2003) Parasite-specific trypanothione reductase as a drug target molecule. Parasitol Res 90(suppl 2):S77–S85

    Article  PubMed  Google Scholar 

  • Krylov DM, Koonin EV (2001) A novel family of predicted retroviral-like aspartyl proteases with a possible key role in eukaryotic cell cycle control. Curr Biol 11:R584–R587

    Article  CAS  PubMed  Google Scholar 

  • Kulkarni MM, Reddy N, Gude T, McGwire BS (2013) Voriconazole suppresses the growth of Leishmania species in vitro. Parasitol Res 112:2095–2099

    Article  PubMed  Google Scholar 

  • Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J et al (2001) Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65:87–89

    CAS  PubMed  Google Scholar 

  • Liese J, Schleicher U, Bogdan C (2008) The innate immune response against Leishmania parasites. Immunobiology 213:377–387

    Article  CAS  PubMed  Google Scholar 

  • Mahmoudzadeh-Niknam H, McKerrow JH (2004) Leishmania tropica: cysteine proteases are essential for growth and pathogenicity. Exp Parasitol 106:158–163

    Article  CAS  PubMed  Google Scholar 

  • Mannion-Henderson J, Flaspohler JA, Lemley KR, Rickoll WL, Parsons M (2000) Isolation and characterization of Leishmania mutants defective in glycosomal protein import. Mol Biochem Parasitol 106:225–237

    Article  CAS  PubMed  Google Scholar 

  • Marovich MA, Lira R, Shepard M, Fuchs GH, Kruetzer R, Nutman TB et al (2001) Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis 33:1076–1079

    Article  CAS  PubMed  Google Scholar 

  • Marrapu VK, Srinivas N, Mittal M, Shakya N, Gupta S, Bhandari K (2011) Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents. Bioorg Med Chem Lett 21:1407–1410

    Article  CAS  PubMed  Google Scholar 

  • Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G (2005) Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40:1395–1403

    Article  CAS  PubMed  Google Scholar 

  • Motta MC (2008) Kinetoplast as a potential chemotherapeutic target of trypanosomatids. Curr Pharm Des 14:847–854

    Article  CAS  PubMed  Google Scholar 

  • Negera E, Gadisa E, Hussein J, Engers H, Kuru T, Gedamu L et al (2012) Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia. Trans R Soc Trop Med Hyg 106:496–503

    Article  CAS  PubMed  Google Scholar 

  • Okwor I, Uzonna JE (2013) The immunology of Leishmania/HIV co-infection. Immunol Res 56:163–171

    Article  CAS  PubMed  Google Scholar 

  • Oliveira-Neto MP, Mattos M, Souza CS, Fernandes O, Pirmez C (1998) Leishmaniasis recidiva cutis in New World cutaneous leishmaniasis. Int J Dermatol 37:846–849

    Article  CAS  PubMed  Google Scholar 

  • Olliaro PL (2010) Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 23:595–602

    Article  CAS  PubMed  Google Scholar 

  • Paniz Mondolfi AE, Stavropoulos C, Gelanew T, Loucas E, Perez Alvarez AM, Benaim G et al (2011) Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother 55:1774–1776

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Plewes KA, Barr SD, Gedamu L (2003) Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infect Immun 71:5910–5920

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Prasad N, Ghiya BC, Bumb RA, Kaushal H, Saboskar AA, Lezama-Davila CM et al (2011) Heat, oriental sore, and HIV. Lancet 377:610

    Article  PubMed  Google Scholar 

  • Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR et al (2005) Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis 40:1148–1155

    Article  CAS  PubMed  Google Scholar 

  • Santos LO, Garcia-Gomes AS, Catanho M, Sodre CL, Santos AL, Branquinha MH et al (2013) Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy. Curr Med Chem 20:3116–3133

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shakya N, Sane SA, Gupta S (2011) Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator—picroliv. Parasitol Res 108:793–800

    Article  PubMed  Google Scholar 

  • Silva-Jardim I, Horta MF, Ramalho-Pinto FJ (2004) The Leishmania chagasi proteasome: role in promastigotes growth and amastigotes survival within murine macrophages. Acta Trop 91:121–130

    Article  CAS  PubMed  Google Scholar 

  • Silva-Lopez RE, Morgado-Diaz JA, Chavez MA, Giovanni-De-Simone S (2007) Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes. Parasitol Res 101:1627–1635

    Article  CAS  PubMed  Google Scholar 

  • Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A et al (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266–1272

    Article  CAS  PubMed  Google Scholar 

  • Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R et al (2007) Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44:350–356

    Article  CAS  PubMed  Google Scholar 

  • Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L et al (2008) Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78:210–211

    PubMed  Google Scholar 

  • Soto J, Rea J, Valderrama M, Toledo J, Valda L, Ardiles J et al (2009) Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 81:387–389

    CAS  PubMed  Google Scholar 

  • Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M (2006) Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100(suppl 1):S26–S33

    Article  CAS  PubMed  Google Scholar 

  • Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S et al (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377:477–486

    Article  CAS  PubMed  Google Scholar 

  • Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N et al (2013) Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health 18:96–100

    Article  CAS  PubMed  Google Scholar 

  • ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46:1702–1709

    Article  PubMed  Google Scholar 

  • Ueno N, Wilson ME (2012) Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival. Trends Parasitol 28:335–344

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • van Griensven J, Diro E, Lopez-Velez R, Boelaert M, Lynen L, Zijlstra E et al (2013) HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis 13:251–259

    Article  CAS  PubMed  Google Scholar 

  • Williams RA, Tetley L, Mottram JC, Coombs GH (2006) Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 61:655–674

    Article  CAS  PubMed  Google Scholar 

  • Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM (2003) Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3:87–98

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, Center for Microbial Interface Biology, The Wexner Medical Center, The Ohio State University, Doan N1145, 410 W. 10th Avenue, Columbus, OH, 43210, USA

    Bradford S. McGwire M.D., Ph.D.

Authors
  1. Bradford S. McGwire M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradford S. McGwire M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology, The Ohio State University, Columbus, Ohio, USA

    Abhay Satoskar

  2. Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA

    Ravi Durvasula

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

McGwire, B.S. (2014). Treatment Modalities for Cutaneous and Visceral Leishmaniasis. In: Satoskar, A., Durvasula, R. (eds) Pathogenesis of Leishmaniasis. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9108-8_6

Download citation

Publish with us

Policies and ethics

Search

Navigation